This article is more than 5 years old. Information may no longer be current.
Half-dose verteporfin PDT has positive outcomes in central serous chorioretinopathy
Click Here to Manage Email Alerts
Half-dose verteporfin photodynamic therapy may be as effective as but safer than a full dose in treating patients with chronic central serous chorioretinopathy, according to a study.
The retrospective study included 204 eyes of 204 patients with central serous chorioretinopathy who were treated with half-dose verteporfin PDT in a 4-year time period at Surugadai Nihon University Hospital, Tokyo.
At 12 months, 182 eyes had complete resolution of serous retinal detachment. Mean best corrected visual acuity improved from 0.11 at baseline to –0.01 (P < .0001).
Eleven eyes had persistent serous retinal detachment, and 12 eye had a recurrence of serous retinal detachment.
Serious complications of full-dose therapy include retinal pigment epithelium atrophy, choroidal ischemia and secondary choroidal neovascularization; however, no serious complications and no serious reductions in visual acuity were reported with half-dose therapy in this study.
“Because the differences in their anatomic success rates and improvement of BCVA were not significant between standard PDT and half-dose PDT, half-dose PDT seems safer,” the study authors said.
Disclosure: The authors have no relevant financial disclosures.
Click Here to Manage Email Alerts